Rhopressa FDA Approval History
FDA Approved: Yes (First approved December 18, 2017)
Brand name: Rhopressa
Generic name: netarsudil
Dosage form: Ophthalmic Solution
Company: Aerie Pharmaceuticals, Inc.
Treatment for: Glaucoma
Rhopressa (netarsudil ophthalmic solution) is a Rho kinase inhibitor for the treatment of open-angle glaucoma or ocular hypertension.
Development timeline for Rhopressa
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.